Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

ClinicalTrials.gov ID: NCT00308581

Public ClinicalTrials.gov record NCT00308581. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 20, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohn's Disease Patients With Prior Loss of Response or Intolerance to Infliximab

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over 26 weeks in patients suffering from Crohn's Disease (CD) and previously treated with infliximab

Study identification

NCT ID
NCT00308581
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Pharma
Industry
Enrollment
539 participants

Conditions and interventions

Interventions

Biological · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2006
Primary completion
Mar 31, 2008
Completion
Mar 31, 2008
Last update posted
Aug 6, 2018

2006 – 2008

United States locations

U.S. sites
31
U.S. states
22
U.S. cities
31
Facility City State ZIP Site status
Not listed San Francisco California
Not listed Gainesville Florida
Not listed Atlanta Georgia
Not listed Chicago Illinois
Not listed Indianapolis Indiana
Not listed Lexington Kentucky
Not listed Louisville Kentucky
Not listed Baton Rouge Louisiana
Not listed Baltimore Maryland
Not listed Boston Massachusetts
Not listed Rochester Minnesota
Not listed Lincoln Nebraska
Not listed Great Neck New York
Not listed New York New York
Not listed Chapel Hill North Carolina
Not listed Charlotte North Carolina
Not listed Cincinnati Ohio
Not listed Cleveland Ohio
Not listed Oklahoma City Oklahoma
Not listed Portland Oregon
Not listed Philadelphia Pennsylvania
Not listed Pittsburgh Pennsylvania
Not listed Charleston South Carolina
Not listed Germantown Tennessee
Not listed Kingsport Tennessee
Not listed Nashville Tennessee
Not listed Dallas Texas
Not listed Galveston Texas
Not listed Houston Texas
Not listed Seattle Washington
Not listed Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00308581, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 6, 2018 · Synced Sep 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00308581 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →